Antimicrobials are substance that kills microorganisms such as bacteria or mold, or stops them from growing and causing disease.
Experts at the European Committee on Antimicrobial Susceptibility Testing, who define the optimal drug concentrations to inhibit the growth of pathogens, have found that genetic methods cannot yet be used to test for susceptibility in a number of important bacterial species.
The U.S. Food and Drug Administration is requesting a total budget of $5.1 billion to protect and promote the public health as part of the President's fiscal year (FY) 2017 budget – an eight percent increase over the enacted budget for FY 2016.
The University of Leicester has been awarded over £1.5 million in order to advance knowledge and understanding in three key areas that impact on health.
The California Veterinary Medical Association (CVMA) applauds Governor Jerry Brown for signing SB 27 (Hill) into law. This bill sets aggressive, groundbreaking standards for antimicrobial drug use in California livestock and will positively impact antibiotic resistance in both humans and animals.
Australian researchers from The University of Queensland have launched a global search to discover antibiotics capable of combating superbug bacteria that are resistant to current antibiotics.
Borrelidin is a naturally occurring antibiotic isolated from the Streptomyces species and initially from Streptomyces rochei in 1949. It is called Borrelidin because it was firstly discovered as having anti-Borrelia activity. Borrelia is a type of bacteria...
The European Society for Clinical Microbiology and Infectious Diseases (ESCMID) has been joined by the World Health Organisation (WHO) to launch the 7th annual ‘International Day for Fighting Infection’ (April 24th, 2015).
A one-day prevalence survey of 183 hospitals found that approximately 50 percent of hospitalized patients included in the survey were receiving antimicrobial drugs, and that about half of these patients were receiving 2 or more antimicrobial drugs, according to a study in the October 8 JAMA, a theme issue on infectious disease. Most antimicrobial use was for infection treatment.
TAXIS Pharmaceuticals, Inc. today announced the acquisition of a group of novel antimicrobial drug candidates from Biota Pharmaceuticals Inc. of Atlanta, GA.
The basic idea of cancer chemoprevention is to arrest or reverse the progression of premalignant cells towards full malignancy, using physiological mechanisms that do not kill healthy cells.
Developing and testing a new anti-cancer drug can cost billions of dollars and take many years of research.
Spring cleaning often involves chlorine bleach, which has been used as a disinfectant for hundreds of years. But our bodies have been using bleach's active component, hypochlorous acid, to help clean house for millennia. As part of our natural response to infection, certain types of immune cells produce hypochlorous acid to help kill invading microbes, including bacteria.
Approximately 80 years ago the first antibiotic was discovered by Sir Alexander Fleming, for which he was justifiably awarded the Nobel Prize in medicine.
Leon Cantas' doctoral research shows that the immune response of the host to a bacterial infection may have a significant effect on the development of bacteria's resistance to antibiotics.
Ceram, the international materials testing and development company, has announced that it is now offering microbiology testing services for the healthcare industries, thanks to a partnership with a leading UK microbiological testing lab.
NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biotechnology company focused on addressing the large unmet therapeutic needs of the global anti-infective market with first-in-class compounds such as its proprietary Aganocides®, today announced that the World Health Organization (WHO) has approved the international nonproprietary name (INN) “auriclosene” (pronounced awr-rih-CLO-zeen) for the Company’s lead Aganocide® compound NVC-422.
Teleflex Incorporated, a leading global provider of medical devices for critical care and surgery, has announced that Semprus BioSciences, a wholly owned subsidiary of Teleflex Incorporated, has been awarded the initial phase of a $2.3 million research grant from the U.S. Army's Telemedicine and Advanced Technology Research Center (TATRC), located at Fort Detrick, MD.
Biomedical scientists collaborating on translational research at two Buffalo institutions are reporting the discovery of a novel, and heretofore unrecognized, set of genes essential for the growth of potentially lethal, drug-resistant bacteria.
Australian vaccine development company BioDiem Ltd (ASX: BDM) announced today the successful granting of a key European patent for its synthetic antimicrobial compound BDM-I. BDM-I is a novel compound active against a range of pathogenic micro-organisms including bacteria, fungi and protozoa. The patent provides protection around BDM-I as a treatment for vulvovaginitis, a general term for inflammation of the vulva or vagina.
BioDiem recently signed a collaborative agreement with The Royal Melbourne Institute of Technology (RMIT) for the development of non-influenza vaccines using BioDiem’s proprietary live attenuated influenza virus (LAIV) technology.